ESTRO 2024 - Abstract Book

S910

Clinical - CNS

ESTRO 2024

Radionecrosis events occurred in a time range between 10 and 51 months after the first pSRT treatment with a median radionecrosis free survival time of 31 months. Additionally, we observed a trend where the development of RN was more closely associated with non-homogeneous dose distribution (prescription at 80% isodose). No correlation was found between RN and execution of retreatments. Median observed progression free survival was 15.4 months (95% C.I. 13.7 – 23.7).

Conclusion:

This study explored dosimetric parameters that can predict radionecrosis following pSRT. We identified a linear correlation between D16cc values and the likelihood of RN, aiming to offer practical guidance on risk levels for the development of RN. This parameter can also be employed to assess single or multiple treatments, either by converting DVHs to EQD2 or by summing DVHs from repeated treatments.

Keywords: stereotaxis, brain metastases, DVH

References:

[1] Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology